Natera
Clinical genetic testing company specializing in cell-free DNA (cfDNA) diagnostics for oncology, women's health, and organ health.
Natera – About Us (Official Site)Natera, Inc. is a clinical genetic testing company headquartered in Austin, Texas, founded in 2004 (originally as Gene Security Network) by Matthew Rabinowitz and Jonathan Sheena. The company went public on NASDAQ (ticker: NTRA) in July 2015 and has grown into a global leader in cell-free DNA (cfDNA) testing technology.
Natera's product portfolio spans multiple clinical areas: Panorama and Vistara for prenatal screening, Horizon and Empower for carrier and hereditary cancer screening, Anora for miscarriage testing, Spectrum for preimplantation genetic testing, Signatera for cancer recurrence monitoring, Aletra for tumor genomic profiling, and Prospera and Renasight for kidney/organ health. Tests are processed in CAP/CLIA-certified laboratories across approximately 300,000 square feet of lab and office space in Texas, with over 16 million tests processed to date.
At scale, Natera employs more than 6,000 people globally and generated $1.70 billion in revenue in FY2024, growing approximately 36% year-over-year to $2.31 billion in 2025, with a market capitalization of roughly $28 billion. Its clinical evidence base includes over 400 peer-reviewed publications covering more than 3 million patients, and it holds more than 500 issued and pending patents.
As a company whose core business is built on non-invasive genetic diagnostics and liquid biopsy innovation, Natera is directly relevant to any advancement in cfDNA analysis, molecular residual disease detection, or genomic profiling technology.
Ideas that could help Natera
- TEX44 Variant Panel for Unexplained Asthenozoospermia
A targeted genetic diagnostic test that screens men with poor sperm motility for biallelic TEX44 loss-of-function variants, enabling a molecular diagnosis for a subset of idiopathic male infertility cases and guiding clinical management.
Why it helps: Natera already offers reproductive carrier screening and male infertility panels; adding TEX44 is a natural extension of its existing clinical sequencing infrastructure and sales channels to fertility clinics.
- TEX44/CPT1B Genetic Panel for Asthenozoospermia Diagnosis
A targeted next-generation sequencing panel that screens male infertility patients for biallelic TEX44 and CPT1B variants, giving clinicians a molecular diagnosis for a previously unexplained cause of sperm motility failure.
Why it helps: Natera's Horizon carrier screen and preconception product lines target couples undergoing ART; a TEX44/CPT1B variant report would plug directly into their pre-IVF workup offering.